Citadel Advisors
NAGE

Citadel Advisors’s Niagen Bioscience NAGE Stock Holding History

Citadel Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.7K Sell
18,300
-1,700
-9% -$9.18K ﹤0.01% 12168
2025
Q4 		$127K Sell
20,000
-34,500
-63% -$240K ﹤0.01% 11452
2025
Q3 		$508K Buy
54,500
+30,900
+131% +$312K ﹤0.01% 9091
2025
Q2 		$340K Sell
23,600
-8,300
-26% -$82K ﹤0.01% 9517
2025
Q1 		$220K Sell
31,900
-8,500
-21% -$53.4K ﹤0.01% 10266
2024
Q4 		$214K Buy
40,400
+13,800
+52% +$75.6K ﹤0.01% 10319
2024
Q3 		$97.1K Buy
26,600
+8,700
+49% +$27.4K ﹤0.01% 11149
2024
Q2 		$48.9K Sell
17,900
-7,900
-31% -$26.4K ﹤0.01% 11786
2024
Q1 		$89.8K Buy
25,800
+23,000
+821% +$42.6K ﹤0.01% 11500
2023
Q4 		$4K Buy
2,800
+1,100
+65% +$1.53K ﹤0.01% 13538
2023
Q3 		$2.48K Sell
1,700
-5,300
-76% -$8.28K ﹤0.01% 13711
2023
Q2 		$11K Sell
7,000
-40,300
-85% -$60.1K ﹤0.01% 13161
2023
Q1 		$72.4K Sell
47,300
-43,000
-48% -$76.6K ﹤0.01% 11686
2022
Q4 		$152K Buy
90,300
+51,900
+135% +$82.3K ﹤0.01% 10594
2022
Q3 		$47K Buy
38,400
+2,900
+8% +$4.67K ﹤0.01% 11682
2022
Q2 		$59K Sell
35,500
-94,100
-73% -$184K ﹤0.01% 11831
2022
Q1 		$319K Buy
129,600
+108,100
+503% +$295K ﹤0.01% 10461
2021
Q4 		$80K Sell
21,500
-13,600
-39% -$73.4K ﹤0.01% 12945
2021
Q3 		$220K Sell
35,100
-25,400
-42% -$209K ﹤0.01% 11790
2021
Q2 		$597K Sell
60,500
-17,900
-23% -$156K ﹤0.01% 9634
2021
Q1 		$732K Buy
+78,400
New +$621K ﹤0.01% 8844

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's NAGE Position: Q1 2026 in Review

Citadel Advisors increased its Niagen Bioscience (NAGE) stake by 35% in Q1 2026, buying an estimated $750K and bringing the position to 530,477 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #5756.

Citadel Advisors first reported a position in NAGE in Q1 2018 and has held it in 26 quarters since. The position peaked at $2.49M in Q4 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Citadel Advisors held 530,477 shares of Niagen Bioscience worth $2.34M as of Q1 2026.
  • Citadel Advisors bought 138,937 Niagen Bioscience shares in Q1 2026, an estimated $750K.
  • Niagen Bioscience made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5756 holding.
  • Citadel Advisors first reported a position in Niagen Bioscience in Q1 2018 and has held it in 26 quarters since.
  • Citadel Advisors's Niagen Bioscience position peaked at $2.49M in Q4 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.